Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone vs sufentanil PCIA after cesarean section
ChiCTR2500105264Phase 4Not yet recruiting
- Sponsor
- Huainan First People's Hospital
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydromorphone in postoperative pain and Postpartum pain (PPP) (2 arms), sponsored by Huainan First People's Hospital. Primary endpoints: Resting VAS score at 6 hours postoperatively and Incidence of dizziness and drowsiness within 48 hours after surgery. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
hydromorphone
03
Conditions
postoperative painPostpartum pain (PPP)
Beyond the preview
Go deeper on ChiCTR2500105264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105264.